Biocept Announces Presentation at Next Generation Dx Summit
Discussion to Feature Applications of Liquid Biopsies to Identify PDL-1 and CMET Expression in Lung Cancer
"Checkpoint inhibition with anti-PD1 and anti-PDL1 antibodies are
becoming a very significant component in lung cancer therapeutics," said
"Liquid biopsies offer a unique opportunity to profile and monitor
patients with solid tumors such as lung cancer, and we appreciate the
opportunity to share our development milestones and real-world
experience with the scientific community attending this prestigious
industry conference," said
About the Next Generation Dx Summit
The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year's expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement.
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to the potential of our
diagnostic assays to improve the detection and treatment of cancer, our
impact on the field of personalized medicine and diagnostic strategies
(including lung cancer therapeutics), and planned future offerings, such
statements are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. The
reader is cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous risk factors as
set forth in our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150730005340/en/
Investor Contact:
LHA
310-691-7100
jcain@lhai.com
Source:
News Provided by Acquire Media